MRK ▲ +0.4% - Merck & Co., Inc.
$MRK Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
20-NOV-2026 06:46 AM ET
Share this post
More filings for $MRK
MRK ▼ -0.3% - Merck & Co., Inc.Nov 19, 2026MRK ▼ -0.3% - Merck & Co., Inc.Nov 19, 2026MRK ▼ -0.6% - Merck & Co., Inc.Nov 17, 2026MRK ▼ -0.6% - Merck & Co., Inc.Nov 17, 2026MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026MRK ▲ +0.9% - Merck & Co., Inc.Nov 9, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment
